Company Overview

Sartorius Stedim Biotech S.A. is a biopharmaceutical equipment and consumables company specializing in single‑use technologies, process solutions, and laboratory instruments used in the development and manufacturing of biologic drugs. The company operates within the bioprocessing, biotechnology, and life sciences tools industries, serving customers involved in biologics, vaccines, cell and gene therapies, and biosimilars.

The company’s primary revenue drivers are consumables for bioprocessing, filtration systems, fluid management technologies, and process analytical tools. Its customer base consists mainly of biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and research institutions. Sartorius Stedim Biotech is positioned as a leading supplier of single‑use solutions, which reduce contamination risk and increase manufacturing flexibility. The company was formed in 2007 through the combination of Sartorius AG’s bioprocessing division and Stedim S.A., and it has since expanded through organic growth and acquisitions aligned with biologics manufacturing trends.

Business Operations

Sartorius Stedim Biotech operates primarily through a single reporting segment focused on Bioprocess Solutions, encompassing integrated systems used across upstream and downstream biopharmaceutical production. Revenue is largely generated from recurring consumables such as bags, filters, tubing assemblies, and membranes, complemented by equipment sales including bioreactors, chromatography systems, and monitoring instruments.

Operations span both domestic and international markets, with manufacturing, R&D, and commercial activities distributed globally. The company controls proprietary filtration membranes, single‑use assemblies, and process control technologies. It maintains a network of subsidiaries under Sartorius Stedim Biotech Group, and benefits from close operational and strategic alignment with its majority shareholder Sartorius AG, which provides complementary laboratory and weighing technologies.

Strategic Position & Investments

The company’s strategy centers on long‑term growth in biologics manufacturing, with a focus on expanding capacity, increasing penetration of single‑use technologies, and supporting advanced therapy modalities such as cell and gene therapies. Growth initiatives include capacity expansion in consumables manufacturing and increased investment in digital bioprocess monitoring and automation.

Sartorius Stedim Biotech has pursued targeted acquisitions to strengthen its technology portfolio, including BIA Separations, which expanded its chromatography capabilities, and Albumedix, enhancing its position in biologics stabilization and purification. The company also invests in emerging areas such as continuous bioprocessing and advanced filtration, while maintaining a portfolio of specialized subsidiaries supporting core bioprocess applications.

Geographic Footprint

Sartorius Stedim Biotech is headquartered in France, with operational and manufacturing presence across Europe, North America, and Asia‑Pacific. Key production and R&D sites are located in France, Germany, United States, and China, supporting global supply chains for biopharmaceutical customers.

The company serves clients in more than 100 countries, with significant revenue derived from North America and Europe, reflecting the concentration of large biopharmaceutical manufacturers in those regions. Its global footprint enables localized production, technical support, and regulatory alignment, which are critical for multinational biologics manufacturing programs.

Leadership & Governance

Sartorius Stedim Biotech is governed by a management board and supervisory board structure consistent with European public companies. Leadership emphasizes long‑term value creation, operational excellence, and close collaboration with customers to support innovation in biologics manufacturing. Strategic vision is aligned with its majority shareholder Sartorius AG, reinforcing continuity in governance and capital allocation.

Key executives include:

• Joachim Kreuzburg – Chief Executive Officer
• Aline Miller – Chief Financial Officer
• Christophe Dubois – Chief Operations Officer
• Yann Bozec – Head of Strategy and Business Development
• Uwe Gottschalk – Chief Scientific Officer